Navigation Links
Studies Confirm Balloon Sinuplasty(TM) Helps Chronic Sinusitis Patients
Date:4/13/2008

Research Verifies Technology Is Safe, Patient-Friendly, Economical

MENLO PARK, Calif., April 14 /PRNewswire/ -- Two independent studies published this week in American Journal of Rhinology and Annals of Otology, Rhinology, & Laryngology confirm Balloon Sinuplasty(TM) technology safely opens narrow sinuses, is economical and highly satisfactory to chronic sinusitis patients. The peer-reviewed studies analyzed outcomes of more than 1,100 individuals treated with this minimally-invasive balloon technology from Acclarent, a leading developer of innovative medical technologies for ear, nose and throat surgeons.

Chronic sinusitis is an inflammation of the nasal sinuses afflicting an estimated 37 million Americans annually. Symptoms include facial pain or pressure, nasal discharge, difficulty breathing through the nose, and fatigue. Although antibiotics and topical steroids can help many people, approximately 500,000 U.S. patients undergo surgery each year to alleviate the symptoms of chronic sinusitis.

Balloon Sinuplasty(TM) technology is similar in concept to catheters used in the heart for balloon angioplasty. The specially designed devices are threaded into the sinus passageways and gently inflated, widening the passages to promote drainage and resolution of chronic sinusitis symptoms. The technology can be used alone or with standard surgical instrumentation.

Recovery times vary but patients typically return to normal activities within 24 hours of treatment. Since 2005, more than 2,500 sinus surgeons have been trained on this technology and treated more than 25,000 patients.

Studies Confirm Balloon Sinuplasty(TM) Benefits

Patients who underwent sinus surgery using Balloon Sinuplasty(TM) technology were more satisfied, felt better post-operatively and experienced less pain, according to data published in the current issue of American Journal of Rhinology. The 70 patient study also showed the total cost of these procedur
'/>"/>

SOURCE Acclarent, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Gene Studies of Male-Female Differences Often Flawed
2. Two studies published in the Lancet
3. Study of Studies Finds No Risk to Children From Phthalates in Toys
4. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
5. Studies Prove Exercise Can Heal the Body Mind and Soul
6. Studies Shed New Light on Breast Cancer, Treatment
7. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress 2Health News:XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress 3Health News:XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress 4Health News:Veterans Organizations Call For Early Lung Cancer Detection Research 2Health News:HLTH Corporation Announces Fourth Quarter Financial Results 2Health News:HLTH Corporation Announces Fourth Quarter Financial Results 3Health News:HLTH Corporation Announces Fourth Quarter Financial Results 4Health News:HLTH Corporation Announces Fourth Quarter Financial Results 5Health News:HLTH Corporation Announces Fourth Quarter Financial Results 6Health News:HLTH Corporation Announces Fourth Quarter Financial Results 7Health News:HLTH Corporation Announces Fourth Quarter Financial Results 8Health News:HLTH Corporation Announces Fourth Quarter Financial Results 9Health News:HLTH Corporation Announces Fourth Quarter Financial Results 10Health News:HLTH Corporation Announces Fourth Quarter Financial Results 11Health News:HLTH Corporation Announces Fourth Quarter Financial Results 12Health News:HLTH Corporation Announces Fourth Quarter Financial Results 13Health News:HLTH Corporation Announces Fourth Quarter Financial Results 14Health News:HLTH Corporation Announces Fourth Quarter Financial Results 15Health News:HLTH Corporation Announces Fourth Quarter Financial Results 16Health News:HLTH Corporation Announces Fourth Quarter Financial Results 17Health News:HLTH Corporation Announces Fourth Quarter Financial Results 18Health News:HLTH Corporation Announces Fourth Quarter Financial Results 19Health News:HLTH Corporation Announces Fourth Quarter Financial Results 20Health News:HLTH Corporation Announces Fourth Quarter Financial Results 21Health News:CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 2Health News:CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 3Health News:CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 4
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 618th Annual Texas Autism Conference Returns To Corpus Christi Makes Nearly 24300 000 Economic Impact 62267 118th Annual Texas Autism Conference Returns To Corpus Christi Makes Nearly 24300 000 Economic Impact 62267 2OmniActive and Kemin Reach Amicable Settlement in Patent Dispute 62262 1Advanced Health Media Honored at NJ Finest Award Ceremony 62257 1Advanced Health Media Honored at NJ Finest Award Ceremony 62257 2